Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

Completed · Phase 3 · Has a placebo group

Conditions studied: Acute Heart Failure

In brief

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Key facts

Study ID
NCT01870778
Run by
Novartis Pharmaceuticals
People needed
6600
Starts
2013-10-02
Expected to finish
2017-02-01
Last updated by the study team
2018-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.